Targets › PGR
39 programs from 34 companies in 79 trials: 28 Phase 2, 28 Phase 4, 15 Phase 3, 8 Phase 1; Other, Oncology, Psychiatry; next expected readout Nov 2026.
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Depending on the isoform, progesterone receptor functions as a transcriptional activator or repressor..; FUNCTION: [Isoform A]: Ligand-dependent transdominant repressor of steroid hormone receptor transcriptional activity including repression…. (UniProt, P06401)
Open in Phaseline: the race on PGR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, San Francisco | Hormone Replacement Therapy (HRT) Estrogen and progestin replacement | ESR1, ESR2, PGR | Phase 4 | Adhesive Capsulitis of the Shoulder | Dec 2026 |
| Changchun GeneScience Pharmaceutical | Megestrol Acetate Progesterone receptor agonist | PGR | Phase 4 | Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia; Non-small Cell Lung Cancer; Neoadjuvant Chemotherapy; Nutrition Disorders … | Dec 2026 |
| Oregon Health and Science University | Ulipristal acetate Progesterone receptor modulator | PGR | Phase 4 | Contraceptive Usage | Dec 2026 |
| Insel Gruppe AG, University Hospital Bern | Hormone Replacement Therapy (HRT) Transdermal estradiol and oral micronized progesterone replacement | ESR1, ESR2, PGR | Phase 4 | Insomnia | Jan 2027 |
| University of Pennsylvania | Etonogestrel Progesterone receptor agonist | PGR | Phase 4 | Sickle Cell Disease | Mar 2027 |
| University of Utah | Levonorgestrel Progesterone receptor agonist | PGR | Phase 4 | Contraception | Mar 2027 |
| University of Colorado, Denver | Levonorgestrel Progesterone receptor agonist | PGR | Phase 4 | Oral Hormonal Contraceptive Use | Mar 2027 |
| Insud Pharma | Drospirenone (LF111) Mineralocorticoid receptor antagonist; Progesterone receptor agonist | NR3C2, PGR | Phase 4 | Change in Bone Mineral Density; Contraception | Dec 2027 |
| University of Colorado, Denver | Etonogestrel Progesterone receptor agonist | PGR | Phase 4 | Contraception | Dec 2027 |
| University Hospital, Ghent | Desogestrel Progesterone receptor agonist | PGR | Phase 4 | Ovarian Stimulation | Dec 2027 |
| Lori Gawron | Etonogestrel Progesterone receptor agonist | PGR | Phase 4 | Emergency Contraception | Apr 2028 |
| Yale University | Desogestrel Progesterone receptor agonist | PGR | Phase 4 | Contraception | May 2028 |
| Peking Union Medical College Hospital | Femoston 2/10 Estradiol and dydrogesterone hormone replacement therapy | ESR1, PGR | Phase 4 | Functional Hypothalamic Amenorrhea | Jun 2028 |
| University of Pennsylvania | Depot medroxyprogesterone acetate (DMPA) Progestin receptor agonist | PGR | Phase 4 | Sickle Cell Disease (SCD) | Jul 2028 |
| Penn State University | Combined Oral Contraceptive (COC) / Apri (Reclipsen) Oral ethinyl estradiol-based contraceptive; estrogen receptor agonist | ESR1, ESR2, PGR | Phase 4 | Other Disorders of Bone Development and Growth | Dec 2028 |
| The University of Hong Kong | Dydrogesterone Progesterone receptor agonist | PGR | Phase 3 | Subfertility | Nov 2026 |
| Khyber Medical University Peshawar | Danazol Progesterone receptor agonist; Androgen Receptor agonist | PGR, AR | Phase 3 | Beta-Thalassemia | Apr 2027 |
| Leiden University Medical Center | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 3 | Female Contraception | Jun 2027 |
| The University of Hong Kong | Levonorgestrel Progesterone receptor agonist | PGR | Phase 3 | Contraception | Sep 2027 |
| The University of Hong Kong | Ulipristal Acetate Progesterone receptor modulator | PGR | Phase 3 | Contraception | Sep 2027 |
| Christiaan Vinkers | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Treatment-resistant PTSD | Nov 2026 |
| University of Wisconsin, Madison | 18F-fluorofuranylnorprogesterone (18F-FFNP) Progesterone receptor (PR) radioligand | PGR | Phase 2 | Metastatic Cancer; Breast Cancer | Dec 2026 |
| Queensland Centre for Gynaecological Cancer | Levonorgestrel Progesterone receptor agonist | PGR | Phase 2 | Complex Endometrial Hyperplasia With Atypia | Dec 2026 |
| University of Mississippi Medical Center | 17-hydroxyprogesterone caproate (17 OHPC) Progesterone receptor agonist | PGR | Phase 2 | Pregnancy | Jan 2027 |
| Xiaojun Chen | Levonorgestrel Progesterone receptor agonist | PGR | Phase 2 | Atypical Endometrial Hyperplasia | Feb 2027 |
| Bedaya Hospital | Dydrogesterone Progesterone receptor agonist | PGR | Phase 2 | Infertility | Mar 2027 |
| Chelsea and Westminster NHS Foundation Trust | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Labor, Induced | Mar 2027 |
| University of Southern California | Danazol Progesterone receptor agonist; Androgen Receptor agonist | PGR, AR | Phase 2 | Cirrhosis, Liver | Aug 2027 |
| Memorial Sloan Kettering Cancer Center | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Metastatic Breast Cancer | Oct 2027 |
| M.D. Anderson Cancer Center | Levonorgestrel Progesterone receptor agonist | PGR | Phase 2 | Atypical Endometrial Hyperplasia | Nov 2027 |
| Fudan University | Medroxyprogesterone Acetate Progesterone receptor agonist | PGR | Phase 2 | Endometrial Cancer | Dec 2027 |
| OHSU Knight Cancer Institute | Ulipristal Acetate Progesterone receptor modulator | PGR | Phase 2 | Mammography Screening | Dec 2027 |
| Yale University | Etonogestrel Progesterone receptor agonist | PGR | Phase 2 | Contraception | May 2029 |
| University of Virginia | transdermal 17β-E2 with cyclic progestin Estrogen receptor agonist with cyclic progestin | ESR1, ESR2, PGR | Phase 2 | Bone Strength | Dec 2029 |
| University of Chicago | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 2 | Breast Cancer | – |
| Calla Lily Clinical Care | Progesterone Progesterone receptor agonist | PGR | Phase 1 | Luteal Phase Insuffiency; Luteal Support; Smoking; Pregnancy Related … | Dec 2026 |
| FHI 360 | Etonogestrel Progesterone receptor agonist | PGR | Phase 1 | Contraception | Jun 2027 |
| Montefiore Medical Center | Mifepristone Glucocorticoid receptor antagonist; Progesterone receptor antagonist | NR3C1, PGR | Phase 1 | Cervical Preparation | Jun 2027 |
| Premier Research | Levonorgestrel Progesterone receptor agonist | PGR | Phase 1 | Healthy Women | – |
Contraception (8) Atypical Endometrial Hyperplasia (4) Infertility (4) Endometrial Cancer (3) Bone Strength (3) Luteal Phase Insuffiency (2) Luteal Support (2) Pregnancy Related (2) Turner Syndrome (2) Endometrial Endometrioid Adenocarcinoma (2) Breast Cancer (2) Other Disorders of Bone Development and Growth (2)
small molecule (34), mixed (2), protein or peptide (1), other (1)
The University of Hong Kong (3) Yale University (2) University of Pennsylvania (2) University of Colorado, Denver (2) M.D. Anderson Cancer Center (1) Xiaojun Chen (1) Christiaan Vinkers (1) Calla Lily Clinical Care (1) Montefiore Medical Center (1) Queensland Centre for Gynaecological Cancer (1) Premier Research (1) University of Chicago (1) Leiden University Medical Center (1) Changchun GeneScience Pharmaceutical (1) Lori Gawron (1) Fudan University (1) Khyber Medical University Peshawar (1) Chelsea and Westminster NHS Foundation Trust (1) OHSU Knight Cancer Institute (1) University Hospital, Ghent (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.